<DOC>
	<DOCNO>NCT01846650</DOCNO>
	<brief_summary>1. purpose : To conduct relative bioavalability study Capecitabine tablets 500 mg ( Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd. ) versus XELODA® 500 mg tablet ( Manufactured Roche Pharma AG ) 2 . Experimental Design： Two-period crossover design 3 . Test drug : Capecitabine tablet Reference drug : XELODA 4 . Sample size：24</brief_summary>
	<brief_title>A Bioequivalence Study Capecitabine Tablets</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Patients must histopathologically /cytologically confirm breast cancer colorectal cancer，without chemotherapy adjuvant chemotherapy , previously receive one two standard chemotherapy regimens patient ; Age : 1870 year , gender : both，BMI≥17，Eastern Cooperative Oncology Group ( ECOG ) performance status：02，Life expectancy great 3 month ; Patients must normal bone marrow function , liver kidney function ; adequate organ function last 1 week , meet follow : ANC≥1.5×109/L，PLT≥80×109/L , Total bilirubin≤1.5×the upper limit normal , ALT , AST≤2.5×the upper limit normal , creatinine≤1.5×the institutional upper limit normal . Patients retreatment could enrol least 4 week last chemotherapy radiotherapy . Patients must volunteer participate sign informed consent form . Suffering heart , liver , kidney disease severe acute Organ invasion disease ; Prior unanticipated severe reaction fluoropyrimidine therapy , know sensitivity 5fluorouracil , know DPD ( Dihydropyrimidine Dehydrogenase ) deficiency . Pregnant breastfeed female Only bone metastasis lesion , measurable lesion Known brain metastasis history organ transplantation Have longterm systemic steroid therapy Serious diseases vital organ ; malignancy cure Use chemotherapy last 4 week History drug/alcohol addiction positive hepatitis screen include hepatitis B surface antigen , HCV HAV ( IgM ) antibodies Patient abnormal serum calcium level screen visit judge Investigator could lead safety risk patient upon participation trial could interfere conduct trial . Preexisting motor sensory neurotoxicity severity grade 2 NCI CTCAE criterion know , exist uncontrolled coagulopathy . Subjects think unsuitable study investigator ; Inability comply protocol study procedure opinion investigator ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>